Your mission
The Josep Carreras Leukaemia Research Institute (IJC) is a non-profit research institute based in Barcelona dedicated to advancing the understanding of leukemia and related disorders, in collaboration with the University of Barcelona and the Autonomous University of Barcelona.
The IJC has laboratories in 5 clinical campuses: i) Hospital Clínic, ii) Hospital de Sant Pau, iii) Hospital Germans Trias Pujol, iv) Hospital del Mar, and v) Hospital Josep Trueta Girona.
IJC serves as a collaborative center for basic researchers and physicians to work together on fundamental clinical and biological aspects of leukemia.
The IJC offers an excellent work environment based on a multidisciplinary fusion of state-of-the-art ideas and facilities.
Dr. Manel Esteller is the principal investigator of the Cancer Epigenetics Group, which is involved in the analysis of the type and mechanisms of epigenetic alterations in cancer cells, including aberrant changes in DNA methylation and histone modifications in cancer, study of the epigenetics machinery and associated mutations, and finally, testing of epigenetic drugs.
We are looking for a junior postdoctoral researcher in the field of Cancer Immuno-Biology to join Dr. Esteller's Cancer Epigenetics Group.
The scientist will be responsible for conducting experiments to identify mechanisms of response and new combinatorial strategies to increase the efficacy of the HDAC6 inhibitors. The researcher will conduct drug screenings, as well as in vitro and in vivo experiments with HDAC6 inhibitors in combination with bispecific antibodies and chimeric antigen receptor (CAR) to find new combinatorial strategies.
Furthermore, the scientist will perform a genome-wide CRISPR screening to identify new mechanisms of response to HDAC6 inhibitors and will perform gain and loss of function approaches to validate the candidates in vitro and in vivo.
In addition, he/she will perform cutting-edge transcriptomics such as single cell RNA-seq, spatial transcriptomics, and methylome arrays to identify mechanisms underlying the combinatorial strategies and the candidates identified. The scientist should be able to interpret the data, analyze, and supervise students enrolled in the project.
This contract is part of the project CPP2023-010525, funded by MICIU / AEI / 10.13039 / 501100011033 and FEDER, UE.
Your profile
What we need:
PhD in Biomedical Sciences or similar.
Excellent track record of publications related to cancer immunotherapy and identification of mechanisms of response in preclinical in vitro and in vivo human models.
Experience in cancer immunotherapy preclinical models, in vitro and in vivo, particularly bispecific antibodies and chimeric antigen receptors (CAR) T cells is a must.
Experience in the identification and validation of mechanisms of response to cancer therapies is required.
Experience in translational research is required.
Training in animal work is a must.
Experience in epigenetic research and the use of epigenetic drugs is an important plus.
Experience in genetic editing using CRISPR/Cas9 system, shRNA.
Experience in genome-wide CRISPR and drug screenings is also an important plus.
Good communication skills in English and can work independently.
Experience in supervising students.
Motivation to achieve a high quality in your work.
Why us?
What we offer:
3 years contract with the possibility of being extended.
The opportunity to contribute to cutting-edge research projects in Molecular Biology and Deep Learning approaches.
Working in the mixed basic and clinical research environment of the Josep Carreras Leukaemia Research Institute.
The stimulating environment of the Barcelona metropolitan area.
Full-time contract.
Competitive Salary to be further defined depending on candidate experience.
Possible start date: 01/11/2024.
The stimulating environment of the IJC and its scientific network.
How to apply?
Please submit your application by October 25.
About us
What makes us different?
The mission of the Josep Carreras Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer, with a special emphasis on leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
The IJC's vision is to be a world-class reference and excellent research multicampus that contributes to the improvement of results, and the cure of patients affected by leukemia and other malignant hemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.
HR Excellence
In 2019, IJC was honored with the Human Resources Excellence in Research Award by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers.
The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC's commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The IJC is an equal opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.
#J-18808-Ljbffr